Inflammation mediators can induce tubular cell dysfunction with conformational changes of tubule Na+/H+ exchanger, urea, or chloride channels that will influence urine composition independently of any structural damage [14, 64, 65].
That proinflammatory mediators can induce TRP receptor function has been demonstrated in primary human lung cell culture [ 21].
It was recently demonstrated that uterine epithelial cells secrete soluble mediators to the stroma and that these mediators can induce a tolerogenic phenotype in local dendritic cell populations.
Mast cell mediators can induce angiogenesis through their action at different stages of angiogenesis, that is, degradation of the ECM, migration and proliferation of endothelial cells, formation and distribution of new vessels, synthesis of ECM, and pericyte mobilization [ 10, 90].
Though essential for the elimination of invasive antigens, chronic expression of the above mediators can induce a variety of inflammatory disorders, including RA and many other autoimmune diseases [ 2].
It is also well known that systemic inflammatory mediators can induce the synthesis of cytokines within the brain, suggesting that this second stimulus could have its genesis in the periphery (Besedovsky and del Rey, 1996; Pitossi et al., 1997).
Inflammation mediators can induce tubular cell dysfunction with conformational changes of tubule Na+/H+ exchanger, urea, or chloride channels that will influence urine composition independently of any structural damage [ 14, 64, 65].
As a biologically active pro-inflammatory mediator, AA can induce apoptosis through its effects on mitochondria (e.g. calcium uptake into mitochondria, or production of ceramide) [ 1, 2].
Several immune mediators that can induce cross-protection have been described, such as CD4 T-cells, CD8 T-cells and antibodies, including IgA.
P53, a tumor suppressor gene, and P21 (cyclin-dependent kinase inhibitor), a key mediator of p53, can induce cell-cycle arrest in the G1-S checkpoint [ 33, 34].
